Abstract
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a progressive, enduring, and often irre-versible adverse effect of many antineoplastic agents, among which sensory abnormities are common and the most suffering issues. The pathogenesis of CIPN has not been completely understood, and strategies for CIPN prevention and treatment are still open problems for medicine.Objectives: The objective of this paper is to review the mechanism-based therapies against sensory abnormities in CIPN.Methods: This is a literature review to describe the uncovered mechanisms underlying CIPN and to provide a summary of mechanism-based therapies for CIPN based on the evidence from both animal and clinical studies.Results: An abundance of compounds has been developed to prevent or treat CIPN by blocking ion channels, targeting in-flammatory cytokines and combating oxidative stress. Agents such as glutathione, mangafodipir and duloxetine are expected to be effective for CIPN intervention, while Ca/Mg infusion and venlafaxine, tricyclic antidepressants, and gabapentin dis-play limited efficacy for preventing and alleviating CIPN. And the utilization of erythropoietin, menthol and amifostine needs to be cautious regarding to their side effects.Conclusions: Multiple drugs have been used and studied for decades, their effect against CIPN are still controversial ac-cording to different antineoplastic agents due to the diverse manifestations among different antineoplastic agents and complex drug-drug interactions. In addition, novel therapies or drugs that have proven to be effective in animals require further inves-tigation, and it will take time to confirm their efficacy and safety.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call